{"nctId":"NCT02774265","briefTitle":"A Different Approach to Preventing Thrombosis","startDateStruct":{"date":"2016-01","type":"ACTUAL"},"conditions":["Venous Thromboembolism","Pulmonary Embolism"],"count":329,"armGroups":[{"label":"VTE prophylaxis with Enoxaparin 30mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VTE prophylaxis with Enoxaparin 30mg BID"]},{"label":"VTE prophylaxis with Aspirin 81mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VTE prophylaxis with Aspirin 81mg BID"]}],"interventions":[{"name":"VTE prophylaxis with Enoxaparin 30mg BID","otherNames":["Lovenox","Low Molecular Weight Heparin (LMWH)"]},{"name":"VTE prophylaxis with Aspirin 81mg BID","otherNames":["ASA (Acetylsalicylic Acid)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients treated at a level-1 trauma center with any one or more of the following injuries: Pelvis fracture (operative or non-operative), Acetabulum fracture (operative or non-operative), or any operative extremity fracture (proximal to metatarsals/carpals)\n* Age greater than or equal to 18 years old\n\nExclusion Criteria:\n\n* Patients receiving pre-existing confounding prophylaxis or therapeutic anticoagulation (not to include anti-platelet agents) prior to admission or those receiving greater than one dose of LMWH since injury\n* Patients with pre-existing coagulopathy\n* Patients with a previous history of VTE within the last 6 months\n* Patients who are pregnant\n* Patients with CNS or spinal cord injury with potential need for further neurosurgical intervention precluding anticoagulation with aspirin\n* Patients with active bleeding precluding the use of anticoagulation\n* Impaired creatinine clearance \\<30ml/min at the time of randomization\n* History of Heparin Induced Thrombocytopenia or ASA or NSAID allergy\n* Prisoners\n* Non-english speaking patients\n* Patients who have an indication for therapeutic anticoagulation\n* Patients deemed inappropriate for inclusion in the study by their treating physician. Reason must be documented\n* Patients who would not normally receive VTE prophylaxis for their injury","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.","description":"Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Deep Venous Thromboembolism","description":"DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Pulmonary Embolism Events","description":"Bases on imaging obtained for symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":164},"commonTop":[]}}}